Ajanta Pharma Q4 Results Preview: Earnings Growth, Key Expectations & Outlook

Ajanta Pharma Q4 FY26 results date is all set to be announced soon and most investors are awaiting it. Professionals are expecting an increase in revenue due to higher sales and a significant rise in PAT. Ajanta Pharma was listed on the National Stock Exchange (NSE) on 29-May-2000. Ajanta Pharma share has its face value of 2 per share, and its NSE symbol is AJANTPHARM. The company operates in the Healthcare sector and primarily belongs to the Pharmaceuticals industry.

Ajanta Pharma Q4 Results 2026 Preview

• Ajanta Pharma Q4 FY26 revenue is expected to be around Strong Growth Expected, representing a 16-22% YoY increase compared to the same quarter last year.
• Profit After Tax, or PAT, is projected to rise 18-24% YoY.
• EBITDA to rise 17-23%.
• Ajanta Pharma is expected to show Strong Growth Expected in its revenue. 

Click and Sign Up to Get Live Updates on Q4 Results

Ajanta Pharma Share Performance

• Over the past six months, Ajanta Pharma share price has Up by 29% to 2,932.10.
• Moreover, over the past year, the stock has Up by 50%
• Despite this weak short-term performance, Ajanta Pharma stock has delivered a financially sound 240% return over the past 5 years.
• As of today, 20-03-2026, the Ajanta Pharma share price is trading at 2,932.10 per share.

Key Factors to Watch for Ajanta Pharma Q4 Results FY26

• Revenue Growth & Segment Performance – Focus on topline growth in the Pharmaceuticals industry within the Healthcare sector.
• Occupancy Levels & Seat Expansion – Monitor operational expansion and capacity utilisation trends.
• Profitability & Margin Trends – Track EBITDA and PAT margins to evaluate cost control and operating efficiency.
• Order Book & New Client Wins – Watch for updates on new contracts, partnerships, and long-term deals.
• Balance Sheet & Cash Flow Position – Review debt levels, working capital management, and operating cash flows for financial stability.

About Ajanta Pharma

Ajanta Pharma is a pharmaceutical company focused on branded generics, offering products in cardiology, ophthalmology, dermatology, and anti-malarials. It serves both Indian and emerging international markets, emphasizing therapeutic expertise and a diverse product portfolio.

Download the Univest iOS App or Univest Android App to get daily stock recommendations and insightful research pieces!

Final Thoughts

Ajanta Pharma is gear up to announce its Q4 FY26 results. Analysts expect 16-22% revenue growth, a 18-24% rise in PAT, and a 17-23% rise in EBITDA. Ajanta Pharma focuses on revenue growth from order execution, margin improvement, a strong order book, and management.

Stay informed with Univest blogs to get real-time updates on Ajanta Pharma Q4 results FY26. 

Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.

Recent Articles

Siemens Energy Q4 FY26 Earnings Preview Expectations Outlook

Entertainment Network Q4 FY26 Earnings Preview Outlook

Energy Development Q4 FY26 Earnings Preview Outlook

Endurance Technologies Q4 FY26 Earnings Preview Expectations Outlook

eMudhra Q4 FY26 Earnings Preview Expectations Outlook